Astellas Pharma Inc (ALPMY) 15.2650 $ALPMY Pfizer (PFE)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Astellas Pharma Inc (ALPMY) 15.2650 $ALPMY

Pfizer (PFE) Bought Medivation (MDVN), but is it a Good Deal?
Maher Syed - Zacks Investment Research - Mon Aug 22, 4:06PM CDT
Pfizer is paying $14 billion for Medivation Inc, but is it worth it?
MDVN: 80.56 (+0.20), PFE: 34.80 (-0.08), SNY: 38.47 (-0.31)

Cytokinetics' Amyotrophic Lateral Sclerosis Study Enrolled
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:13AM CDT
Cytokinetics (CYTK) reported that it has completed patient enrollment in the phase III amyotrophic lateral sclerosis study on tirasemtiv.
CYTK: 12.07 (-0.02), AMGN: 170.06 (-0.70)

Sanofi's Bid for Medivation Is Too Low
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 28, 1:38PM CDT
Image source: Flickr user StockMonkeys.com. After waiting for weeks for a reply to its M&A offer, drug giant Sanofi has gone public with a $9.3 billion bid to acquire mid-cap cancer drugmaker Medivation  . Sanofi's purchase price is...
MDVN: 80.56 (+0.20), JNJ: 119.34 (-0.13), GILD: 78.38 (+0.46), SNY: 38.47 (-0.31), NVS: 78.77 (-0.57)

J&J's Q1 Results Suggest More Upside for Medivation, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 27, 7:01AM CDT
SOURCE: JOHNSON & JOHNSON Johnson & Johnson has reported its first-quarter financials, and the report shows that market share for its top selling prostate cancer drug Zytiga slipped slightly in the quarter. The loss of market share in...
MDVN: 80.56 (+0.20), JNJ: 119.34 (-0.13)

Medivation/Astellas' Xtandi Gets CHMP Nod to Include Data
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 10:50AM CDT
Medivation (MDVN) and Astellas (ALPMY) announced that the EMA's CHMP has issued a positive opinion in favor of the inclusion of new data in Xtandi's label.
MDVN: 80.56 (+0.20), AZN: 32.81 (-0.40), AMAG: 23.83 (-0.06)

Medivation Prostate Cancer Drug Xtandi under Pricing Attack
Arpita Dutt - Zacks Investment Research - Tue Mar 29, 9:30AM CDT
Americans are charged more for Medivation's (MDVN) prostate cancer drug, Xtandi, compared to countries like Sweden, Japan and Canada.
MDVN: 80.56 (+0.20), VRX: 29.03 (-1.22)

Amgen Kyprolis' Label Expanded, Repatha Approved in Japan
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 3:30PM CST
The label for Amgen's (AMGN) Kyprolis has been expanded in the U.S. and accelerated approval has been converted to full approval; Repatha gains approval in Japan.
AMGN: 170.06 (-0.70), ANIK: 47.24 (-0.21), CELG: 106.74 (-0.28)

Where We Are Headed - Featured Research on Airbus Group, Astellas Pharma, Brambles and Detour Gold
ACCESSWIRE - Fri Jan 22, 8:05AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Airbus Group SE (OTC: EADSY), Astellas Pharma Inc. (OTC: ALPMY), Brambles Ltd. (OTC: BXBLY) and Detour Gold Corp. (OTC: DRGDF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Ironwood Highlights Strategic Objectives, Provides Outlook
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 3:25PM CST
Ironwood Pharmaceuticals (IRWD) provided a comprehensive overview of its initiatives by highlighting three- and five-year operational and financial goals.
AGN: 234.54 (-2.45), IRWD: 13.34 (-0.08), AZN: 32.81 (-0.40)

Vical's VL-2397 Gets Orphan Status for Invasive Aspergillosis
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:50PM CST
Vical's (VICL) antifungal candidate, VL-2397, was granted Orphan Drug designation for the treatment of patients with invasive aspergillosis.
VICL: 3.80 (-0.05), HZNP: 18.80 (-0.21), LGND: 103.31 (-1.00)

Ocata Therapeutics Almost Doubled in November -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Fri Dec 04, 3:03PM CST
What: Shares of eye-disease-focused  Ocata Therapeutics posted a huge 88% gain during the month of November after the company accepted a buyout offer for a healthy premium, according to data from S&P Capital IQ . So what:  Early in the...
OCAT: 8.47 (+0.01)

Ironwood/Astellas Report Positive Phase III Data on Linzess
Zacks Equity Research - Zacks Investment Research - Tue Dec 01, 3:55PM CST
Ironwood Pharmaceuticals (IRWD) and Astellas reported positive top-line phase III data on Linzess; Astellas will file for its approval in Japan in 2016.
AGN: 234.54 (-2.45), IRWD: 13.34 (-0.08), ACHN: 8.26 (-0.10)

Mallinckrodt (MNK) Sells Contrast Media & Delivery Systems
Zacks Equity Research - Zacks Investment Research - Mon Nov 30, 3:55PM CST
Mallinckrodt plc (MNK) announced that it has completed the previously announced divestiture of its global contrast media and delivery systems (CMDS) business to Guerbet for approximately $270 million.
MNK: 74.54 (-0.51), MYL: 42.36 (-0.39), CORT: 5.33 (-0.08)

Roche-Exelixis' Cotellic-Zelboraf Combination Gets EC Nod
Zacks Equity Research - Zacks Investment Research - Thu Nov 26, 12:20PM CST
Roche (RHHBY) received good news when the European Commission (EC) approved its skin cancer drug Cotellic (cobimetinib) for use in combination with Zelboraf (vemurafenib).
LLY: 77.75 (-0.02), EXEL: 11.15 (+0.11)

Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 25, 9:28AM CST
Image source: Johnson & Johnson. Healthcare conglomerate Johnson & Johnson 's share price may be up only marginally since the week began, but make no mistake about it: The week couldn't have possibly started off better for its long-term...
MDVN: 80.56 (+0.20), JNJ: 119.34 (-0.13), AMGN: 170.06 (-0.70), CELG: 106.74 (-0.28)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NUS Unveils eLuminator: A Leap for Robotics & Healthcare

Updated Category News Views 3

Game-Changing Electronic Skin From NUS It's not every day you come across tech that could shake up multiple industries, but that's just what the National University of Singapore has cooked up with their latest brainchild—the eLuminator. This ain't your everyday wearable tech. We're talking a skin-like device that can both detect and show touch in real-time, no fiddly...

Continue Reading
SOA Elects New Leaders for 2026: A Look Ahead

Updated Category News Views 2

A New Lineup for SOA's Board in 2026 On the financial frontlines, few organizations hold the clout that the Society of Actuaries (SOA) wields. With their latest round of elections completed, they've named five fresh Board members along with both a new President Elect and Vice Chair for the upcoming 2026-2027 term. These folks are gearing up to take the stage right after...

Continue Reading
LifeLabs' AI Program: A Manager's New Toolbox

Updated Category News Views 3

Management In the Age of AI: New Frontiers Gone are the days when a simple software update meant staying competitive. We're in a new era, folks—one where AI isn't just a handy tool—it's reshaping entire industries. But here's the kicker: all the fancy tech in the world won't do squat without savvy managers who know how to drive adoption. Yup, that's the naked truth,...

Continue Reading
Hyundai Teases 2027 TUCSON: Global Reveal Imminent

Updated Category News Views 2

Hyundai Sets the Stage for the 2027 TUCSON Hyundai’s ready to roll out its shiny new set of wheels, the 2027 TUCSON, and boy, they sure know how to make an entrance. Mark your calendars for October 1—it's happening right in the Big Apple, none other than Long Island City. Expect the spotlight to hit at precisely 5:15 p.m. ET, and don't worry if you can't snag a...

Continue Reading
Multiply's AI Agent Tackles $126K Google Ads Waste

Updated Category News Views 4

AI Steps In Where Marketers Hit a Wall Picture this: marketers drowning in search terms flying at them faster than they can blink. Multiply's new AI-powered Ad Spend Recovery Agent steps in, claiming to save an eye-watering $126,000 per year by cutting Google Ads waste. Talk about having a hawk-eyed auditor sifting through your accounts. Shaking Up Traditional Automation...

Continue Reading
Derek Pesta Shines: Forbes Top Wealth Advisors 2026

Updated Category News Views 4

An Unwavering Dedication to Clients Every once in a while, the industry tips its hat to someone who truly knows what they're doing. Derek Pesta, head honcho at Pesta & Pesta Wealth Management, has landed on the 2026 Forbes Top Next-Gen Wealth Advisors Best-in-State list. It’s not just a pat on the back; it's a solid nod to the way he runs his game. You know it’s big...

Continue Reading
Perkins Rolls Out Mahjong to Revive Family Bonds

Updated Category News Views 5

Perkins Ditches the Phones, Sparks True Connection No doubt about it, folks—Perkins Restaurant & Bakery has cooked up something special to bring families back to the table. Not just for pancakes or pies this time, but for a little classic game action with their limited-edition Mahjong set. Love it or leave it, this is Perkins tapping into the magic of togetherness...

Continue Reading
BLM's Wild Horse Strategy: Fertility Control's Time to Shine

Updated Category News Views 0

Wild Horse Management Gets a Shot in the Arm Amigo, when the federal government throws $30 million dollars at a problem, you'd hope they're not just throwing us a bone. The Bureau of Land Management (BLM) now has this hefty sum courtesy of the U.S. Department of Agriculture, intended to expand wild horse fertility control across the sprawling landscapes they roam. This...

Continue Reading
Understanding Criminal Threat Charges in Kansas

Updated Category News Views 2

The Intricacies of Criminal Threat Cases in Kansas Let's cut straight to it: not all heated exchanges land you in court, but words can slap you with a criminal threat charge in Kansas if mishandled. A simple spat can turn legal nightmare, making it crucial to grasp the nuances of these cases. What sets them apart from other charges is the absence of physical...

Continue Reading
New Leadership at Newmark: Tech Focus Amplified

Updated Category News Views 4

A Strategic Leap in Tech Leadership Newmark Group, Inc. (NASDAQ: NMRK) has handed the digital reins to Mike Whitaker, bringing him on board as Group Chief Information Officer. If you're in the loop with commercial real estate, this shakeup shouldn't come as a surprise. Newmark's been pretty gung-ho about tightening their tech playbook, and Whitaker's appointment is just...

Continue Reading

Top 5 Most Recently Viewed Articles

Saratoga Investment Corp. Prepares for Financial Results Call

Updated Category News Views 124

Saratoga Investment Corp. Announces Upcoming Financial Report As the end of the fiscal quarter approaches, Saratoga Investment Corp. (NYSE: SAR), a notable player in the business development sector, is gearing up to present its financial outcomes for the quarter that concluded on August 31, 2025. This event is marked by an eagerness to share insights with stakeholders and...

Continue Reading
Whirlpool Corporation to Share Its First-Quarter Results Soon

Updated Category News Views 125

Whirlpool Corporation to Share First-Quarter Results Whirlpool Corporation (NYSE: WHR) is gearing up to announce its first-quarter financial results on April 23rd, presenting an opportunity for stakeholders to gain insights into the company's performance. This announcement is eagerly anticipated by investors, highlighting Whirlpool's commitment to transparency and...

Continue Reading
ISASecure Launches New Certification to Enhance IACS Security

Updated Category News Views 197

ISASecure Introduces ACSSA Certification for Enhanced Security The International Society of Automation (ISA) has unveiled a significant initiative, aimed at optimizing security protocols for industrial automation systems. The new inspection and certification scheme, known as the Industrial Automation Control System Security Assurance (ACSSA), is set to streamline the...

Continue Reading
Sitio Royalties Stock Hits 52-Week Low: Factors at Play

Updated Category News Views 101

Understanding the Recent Activity of Sitio Royalties Corp In an unpredictable market landscape, Sitio Royalties Corp (NYSE: STR) has recently seen its stock plummet to a 52-week low of $19.87. This shift raises concerns amongst investors, particularly as technical indicators point towards the stock being oversold. Despite the current market turbulence, the company boasts...

Continue Reading
ThreeD Capital Inc. Strengthens Investor Connections for Growth

Updated Category News Views 155

ThreeD Capital Inc. Enhances Investor Relations In a recent move to bolster its investor relations strategy, ThreeD Capital Inc. (CSE: IDK / OTCQX: IDKFF), a Canadian venture capital firm known for its focus on junior resources and disruptive technologies sectors, has announced a renewed agreement with PHK Investments LLC. This strategic partnership aims to enhance the...

Continue Reading